SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zim Laboratories - Quaterly Results

10 Feb 2025 Evaluate
A slight decline in the revenue of Rs. 953.95 millions was seen for the December 2024 quarter as against Rs. 958.19 millions during year-ago period.The Company's Net profit for the December 2024 quarter have declined marginally to Rs. 43.50  millions as against Rs. 48.30 millions reported during the corresponding quarter ended.OP of the company witnessed a marginal growth to 135.30 millions from 122.83 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 953.95 958.19 -0.44 2671.20 2480.86 7.67 3654.73 3965.31 -7.83
Other Income 17.65 11.06 59.58 40.67 31.59 28.74 46.91 64.31 -27.06
PBIDT 135.30 122.83 10.15 321.00 278.38 15.31 447.94 576.21 -22.26
Interest 27.33 16.96 61.14 84.77 46.47 82.42 69.24 55.75 24.20
PBDT 107.97 105.87 1.98 236.23 231.91 1.86 378.70 520.46 -27.24
Depreciation 47.68 35.78 33.26 146.57 109.55 33.79 148.29 161.28 -8.05
PBT 60.29 70.09 -13.98 89.66 122.36 -26.72 230.41 359.18 -35.85
TAX 16.79 21.79 -22.95 26.40 33.71 -21.68 62.84 109.09 -42.40
Deferred Tax 10.21 8.80 16.02 15.36 12.53 22.59 54.55 46.30 17.82
PAT 43.50 48.30 -9.94 63.26 88.65 -28.64 167.57 250.09 -33.00
Equity 487.26 487.26 0.00 487.26 487.26 0.00 487.26 487.26 0.00
PBIDTM(%) 14.18 12.82 10.64 12.02 11.22 7.09 12.26 14.53 -15.66

Zim Laboratories Share Price

76.00 -0.08 (-0.11%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×